Luncheon symposium & Poster presentation

1 ÀýÁ¦°¡ ºÒ°¡´ÉÇÑ ´ã°ü¾Ï¿¡¼­ S-1 °æ±¸Ç×¾ÏÈ­Çпä¹ý°ú º´ÇàÇÑ CyberKnife radiosurgery: Áõ·Ê º¸°í ¹ÚÁø¼®(ÀÎÇÏ´ë)
2 ±¤¿ªµ¿ Ä¡·á·Î ÁÁÀº ¹ÝÀÀÀ» º¸ÀÎ ±¹¼ÒÀû ÁøÇ༺ °£¹®ºÎ¾Ï ȯÀÚ 1¿¹ Àü¼º°ï(¼øõÇâ´ë)
3 Chemotherapy in Patients with Biliary Tract Cancer: A Single-Institution Experience ÃÖÄ¡ÈÆ(ÇѸ²´ë)
4 Rupture of CBD in Patient with Metastatic Biliary Obstruction À±ÁöÀº(ÇѸ²´ë)
5 °£µ¿¸Æ ÁÖÀÔ Ç×¾Ï È­ÇÐ ¿ä¹ýÀ¸·Î ¿ÏÀü °üÇØµÈ ´ã³¶¾Ï 1¿¹ ±èµ¿Èñ(¿µ³²´ë)
6 An early phase II trial of S-1 and concurrent chemoradiotherapy in patients with locally advanced biliary tract cancer ¼­ÁÖÈñ(¿¬¼¼´ë)
7 ´ëÀå ¹Ì¼Ò ¿ëÁ¾¿¡¼­ ¹ß°ßµÈ ¿ø¹ß¼º ¹ÝÁö¼¼Æ÷¾ÏÁ¾ 1¿¹ ¿ÀÈñÁÖ(¿µ³²´ë)
8 Rectal cancer and nasopharyngeal metastasis ±è»óÈñ(°¡Å縯´ë)
9 Dual self-expandable metal stent »ðÀÔÀ¸·Î Áõ»ó È£ÀüµÈ ´©°øÀ» µ¿¹ÝÇÑ ¾Ç¼º ´ëÀåÇùÂø 1·Ê ¼­À¯½Â(¼øõÇâ´ë)
10 Á÷Àå¾Ï °£ÀüÀÌ·Î Ç×¾ÏÄ¡·á Áß ¹ß»ýÇÑ ÁÖÆóÆ÷ÀÚÃæ(pneumocystis carinii) Æó·Å 1¿¹ ½ÅÀº°æ
11 Colitic cancer ¿¹¹æÀ» À§ÇÑ InfliximabÀÇ step down therapy strategy ±èºÀȯ(ºÐ´çÁ¦»ýº´¿ø)
12 Á÷Àå¿¡ ¹ß»ýÇÑ ¿ø¹ß¼º ¹Ì¸¸¼º BÇü ´ë¼¼Æ÷ ¸²ÇÁÁ¾ 2¿¹ ±èµ¿Èñ(¿µ³²´ë)
13 °£ ÀüÀ̸¦ µ¿¹ÝÇÑ ½ÄµµÀÇ ±âÀú¼¼Æ÷¾ç ÆíÆò¼¼Æ÷¾Ï 1¿¹ ÀÌÀÀ°©(°æºÏ´ë)
14 Complete Response in a Case of Advanced Esophageal Cancer Treated by Mono-Chemotherapy of TS-1. ±èµ¿¿í(ºÎ»ê´ë)
15 ÀþÀº ¼ºÀο¡¼­ ¹ß»ýÇÑ ¿ø¹ß¼º °øÀå ¼±¾ÏÁ¾ 1¿¹ ¹ÚÀçÀº(°¡Å縯´ë)
16 A case of Primary mesenteric root mesothelioma, mimicking sclerosing mesenteritis. À±¿µÈÆ(Á¦ÁÖÇѶ󺴿ø)
17 ¹é¼­¿¡¼­ methotrexate¿¡ ÀÇÇÏ¿© À¯¹ßµÈ Àå±â¹«°Ô ¹× üÁß º¯È­¿Í Àå³»¼¼±ÕÀüÀ§¿¡ ´ëÇÑ ´Ü±â°£ ±Ý½ÄÀÇ È¿°ú ±èÁ¤¿í(Áß¾Ó´ë)
18 °£¿ÜÀüÀ̸¦ µ¿¹ÝÇÑ ÁøÇ༺ °£¼¼Æ÷¾Ï¿¡¼­ °æµ¿¸ÆÈ­ÇлöÀü¼ú°ú °í°­µµÁý¼ÓÃÊÀ½ÆÄ ÀÀ°í¼ú º´ÇÕÄ¡·á 1·Ê ¿ì¼º¿ë(°¡Å縯´ë)
19 ½ºÅÙÆ® »ðÀÔ ¹× Ç׾Ͽä¹ý ÈÄ ±ÙÄ¡Àû ÀýÁ¦¼úÀ» ½ÃÇàÇß´ø Æó¼â¼º ±¹¼Ò ħ¹ü °øÀå ¼±¾Ï 1¿¹ ±èÇü±â(¼øõÇâ´ë)
20 Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer ±èÀ±Àç(¿¬¼¼´ë)
21 Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer ±èÈñ¸¸(¿¬¼¼´ë)
22

Weekly Full-dose Gemcitabine and Single-dose Cisplatin with Concurrent Radiotherapy in Patients with Locally Advanced Pancreatic Cancer È«¼ºÇÊ(¿¬¼¼´ë)
23

Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment in Locally Advanced or Metastatic Pancreatic Cancer ¿øÁ¾Áø(µ¿¾Æ´ë)
24 Efficacy of Erlotinib plus Gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer ¹Ú¼¼¹Ì(¿¬¼¼´ë)
25 FOLFOX4 as a rescue chemotherapy in gemcitabine based chemotherapy refractory pancreatic cancer Á¤ÁÖ¿ø(¿¬¼¼´ë)
26 À§¾Ï ¼¼Æ÷ÁÖ¿¡¼­ AstaxanthinÀÇ Ç×¾Ï È¿°ú¿¡ °üÇÑ ¿¬±¸ À̹üÀç(°í·Á´ë)
27 À§ ÀüÁ¤ºÎ¿¡¼­ ¹ß»ýÇÑ À§¼±¾Ï°ú µ¿¹ÝµÈ ½Å°æ³»ºÐºñ¾ÏÀÇ È¥ÇÕÁ¾¾ç 1¿¹ À̼ҿµ(°¡Å縯´ë)
28 ÁøÇ༺ À§¾ÏÀÇ ±ÙÄ¡Àû À§ÀýÁ¦¼ú ÈÄ Epirubicin , Cisplatin , 5-FluorouracilÀÇ º¹ÇÕ º¸Á¶Ç׾Ͽä¹ýÀÇ Ä¡·áÈ¿°ú ¿øÁ¾Áø(µ¿¾Æ´ë)
29 Ç×¾Ï Ä¡·áÁßÀÎ À§¾Ï ȯÀÚ¿¡¼­ ÇǺÎÀüÀÌ·Î ¿ÀÀÎµÈ ½ºÆĸ£°¡´®Áõ ÀÌÁö¼÷(°í½Å´ë)
30 ÁøÇ༺À§¾ÏȯÀÚ¿¡¼­ Ç׾Ͽä¹ý ¹ÝÀÀÀ» ¿¹ÃøÇϱâ À§ÇÑ ¾Æµ¥³ë½Å 3Àλê/Ç×¾ÏÁ¦¹ÝÀÀ°Ë»ç(ATP-CRA)ÀÇ »ç¿ë ±èÈ«Á¤(¿¬¼¼´ë)
31 À§ ¸²ÇÁÁ¾À¸·Î ¿ÀÀÎµÈ ¿ø¹ß¼º À§ ¼Ò¼¼Æ÷¾Ï À¯½Âö(°¡Å縯´ë)
32 °£¼¼Æ÷¾Ï°ú À§½ÄµµÁ¢ÇպΠ¼±¾Ï ±×¸®°í ÇÏÀεξÏÀ» µ¿¹ÝÇÑ »ïÁß¾Ï 1¿¹ ¹ÚÀºÈ£(°í½Å´ë)
33 A pilot study of preoperative concurrent chemoradiotherapy with S-1 and cisplatin in locally advanced gastric cancer Á¤À±¼÷(¿¬¼¼´ë)